Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways.
Timo Buhl, Mathias Sulk, Pawel Nowak...
https://pubmed.ncbi.nlm.nih.gov/25848978/Actively Recruiting
Led by Narrows Institute for Biomedical Research · Updated on 2025-05-06
20
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are evaluating the effectiveness of Clascoterone cream 1% in reducing the size of sebaceous glands in adults with acneiform rosacea, specifically papulopustular rosacea. This Phase 2 study aims to assess both the treatments impact on gland size and its safety profile during a 12-week treatment period. Participants will use Clascoterone 1% cream topically on affected facial areas. The study includes adults diagnosed with papulopustular rosacea who apply the cream regularly for 12 weeks. There is no placebo group or masking in this trial. During the study, researchers will perform biopsies to measure sebaceous gland size before and after treatment. They will also take digital photographs to document clinical changes, and collect both physician and participant assessments. Safety and any adverse events will be monitored throughout the 12-week period to evaluate the overall effects of the cream.
CONDITIONS
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
K
Kayla N Zafar, BA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Narrows Institute for Biomedical Research
Lead Sponsor
Sun Pharmaceutical Industries Limited
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Clascoterone 1% Cream (Investigational) | Topical Metronidazole or Azelaic Acid (Standard Therapy) |
|---|---|---|
| What it is | A topical androgen receptor inhibitor cream tested for facial papulopustular rosacea. All participants in the trial apply clascoterone 1% to affected skin. | Topical metronidazole or azelaic acid, established anti-inflammatory creams commonly used as standard treatment for papulopustular rosacea. |
| Primary use | Reduction in size of facial sebaceous glands and improvement in rosacea lesions assessed after 12 weeks of use. | To decrease the number and severity of papules and pustules, reduce facial redness, and control inflammation for type 2 rosacea. |
| How it is given or performed | Clascoterone 1% cream is applied to affected facial skin as directed over 12 weeks, with protocol adherence and product consistency required. | Metronidazole gel/cream or azelaic acid gel is generally applied to clean facial skin once or twice daily as part of ongoing rosacea management. |
| Evidence status | Clinical efficacy and safety for papulopustular rosacea are still under investigation in this small single-arm study; no results posted. | Multiple clinical trials and guideline review support the routine efficacy of topical metronidazole or azelaic acid in reducing papules, pustules, and facial redness from type 2 rosacea. |
| Important limitations | This is a small, single-arm, open-label study; results may not generalize to the broader rosacea population, and comparative effectiveness with established topical treatments remains unknown. | Metronidazole and azelaic acid can cause skin irritation or stinging and may not control all features of rosacea. Their effectiveness is supported in population-level studies, but individual response varies. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks
Participants apply Clascoterone Cream 1% to treat facial acneiform rosacea.
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Timo Buhl, Mathias Sulk, Pawel Nowak...
https://pubmed.ncbi.nlm.nih.gov/25848978/Nasr Y Khalil, Ibrahim A Darwish, Abdulmohsen A Al-Qahtani
https://pubmed.ncbi.nlm.nih.gov/32164966/Jonathan Wilkin, Mark Dahl, Michael Detmar...
https://pubmed.ncbi.nlm.nih.gov/15153893/Megan Brelsford, Trisha Clarke Beute
https://pubmed.ncbi.nlm.nih.gov/18786498/Aikaterini I Liakou, Jens R Nyengaard, Stefanos Bonovas...
https://pubmed.ncbi.nlm.nih.gov/27250651/J Tan, H Schöfer, E Araviiskaia...
https://pubmed.ncbi.nlm.nih.gov/26915718/Narrows Institute for Biomedical Research
Lead Sponsor
Sun Pharmaceutical Industries Limited
Collaborating Sponsor